Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

CompletedPhase 2

NCT03244956

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Re…

This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV6…

France40 participantsStarted 2017-12-27

Treatment: Trametinib, Dabrafenib